Literature DB >> 2646076

Immunocytology in malignant pleural mesothelioma. Expression of tumor markers and distribution of lymphocyte subsets.

J Guzman1, K J Bross, G Würtemberger, U Costabel.   

Abstract

We studied the reactivity of malignant mesothelioma cells with tumor markers and the phenotypes of lymphocyte subsets in pleural effusions from 14 patients with malignant mesothelioma. For identification of cell surface antigens with monoclonal antibodies, the adhesive slide assay was used. The reaction pattern of mesothelioma cells was found to be CEA negative, Leu M1 negative, EMA positive, BMA-120 positive, My 4 positive, and BA-2 positive. The surface morphology of mesothelioma cells may be of additional help for diagnosis. By these markers, the distinction between mesotheliomas and carcinomas is facilitated. The differentiation of reactive benign mesothelial hyperplasia from malignant mesothelioma by surface marker staining is not yet possible, however. In many effusions in this study, a concomitant T-lymphocytosis was observed with a non-specific increase in the CD4/CD8 ratio, as known for other pleural diseases.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2646076     DOI: 10.1378/chest.95.3.590

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  3 in total

1.  Demonstration of estrogen and progesterone receptors as well as Ki-67 and p-145 antigens in single tumor cells from blood and pleural effusions using a slide assay.

Authors:  F W Hirsch; P Deibert; H Busch; G W Löhr; K J Bross
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 2.  Diagnostic tests in pleural effusion--an update.

Authors:  N Berkman; M R Kramer
Journal:  Postgrad Med J       Date:  1993-01       Impact factor: 2.401

3.  Immunocytochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: IOB3--a new tumor marker.

Authors:  C S Kortsik; P Werner; N Freudenberg; J C Virchow; C Kroegel; M Pott; H Matthys
Journal:  Lung       Date:  1995       Impact factor: 2.584

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.